Summarized by Masters of Longevity from Longevity Technology.
Longeveron will outline recent progress in its regenerative cell therapy programs, offering investors and readers an update on development strategies and clinical focus.
Key Takeaways
- The company will present at the H.C.
- Its lead investigational product is an allogeneic bone marrow-derived mesenchymal stem cell therapy aimed at pro-regenerative and anti-inflammatory effects.
- Development programs target hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty with multiple FDA designations reported.
